249583-84-4

Usage

Uses

Used in Pharmaceutical Research and Development:
5-Acetyl-2-cyanopyridine is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure and reactivity allow for the creation of diverse chemical entities with potential medicinal applications.
Used in Agrochemical Production:
In the agrochemical industry, 5-Acetyl-2-cyanopyridine is employed as a precursor for the production of various agrochemicals, including pesticides and herbicides. Its role in these applications is to provide a foundation for the synthesis of compounds that can effectively control, manage, or eliminate pests and weeds in agricultural settings.
Used in the Synthesis of Heterocyclic Compounds:
5-Acetyl-2-cyanopyridine is used as a starting material in the synthesis of heterocyclic compounds, which are an important class of organic compounds with a ring structure containing atoms of at least two different elements. These heterocyclic compounds have a wide range of applications, including in pharmaceuticals, dyes, and other specialty chemicals.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-Acetyl-2-cyanopyridine is used to construct more complex organic molecules. Its presence in the synthesis process allows for the creation of a variety of organic compounds with different functional groups and properties, expanding the scope of chemical research and development.
Used in Chemical Research:
Due to its diverse potential applications and unique chemical properties, 5-Acetyl-2-cyanopyridine is also used in chemical research to explore new reactions, mechanisms, and the development of novel synthetic methodologies. This research can lead to advancements in the understanding of chemical processes and the discovery of new applications for 5-Acetyl-2-cyanopyridine.

InChI:InChI=1/C8H6N2O/c1-6(11)7-2-3-8(4-9)10-5-7/h2-3,5H,1H3

Upstream product

• 84575-40-6 5-(1,1-ethylenedioxyethyl)pyridine-2-carbonitrile 
• 350-03-8 methyl-3-pyridylketone 
• 151-50-8 potassium cyanide 
• 55675-95-1 3-(1,1-ethylenedioxyethyl)pyridine N-oxide 
• 14188-94-4 3-acetylpyridine N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 139042-59-4 1-(6-bromopyridin-3-yl)ethanone 
• 55676-25-0 3-(2-methyl-[1,3]dioxolan-2-yl)-pyridine 

Downstream Products

• 65184-39-6 5-acetylpicolinic acid 
• 249583-83-3 5-(1-hydroxyethyl)pyridine-2-carbonitrile 

Relevant academic research and scientific papers

Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

Preparation of cyanopyridines by direct cyanation

After pretreatment with nitric acid and trifluoroacetic anhydride, aqueous potassium cyanide converted pyridines 1a-1 into their corresponding 2-cyano derivatives 4a-1 in an average yield of 52%. Georg Thieme Verlag Stuttgart.

1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF

This invention provides a compound represented by the formula (I) :wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

1-Imidazolylcarbonyloxy-substituted tetrahydroquinolines and pyridines: Synthesis and evaluation of P450 TxA2 inhibition

The title compounds are derived from our model describing structural requirements for strong P450 TxA2 inhibition. In the present paper the syntheses of the 1-imidazolylcarbonyloxy-substituted tetrahydroquinolines 1, 3, and 4, tetrahydro-naphthalene 2 and 3-ethylpyridines 5 and 6 are described. Using our P450 TxA2 inhibition assay, 1-6 were tested for enzyme inhibitory activity. Compound 1 (5-(1-imidazolylcarbonyloxy)-5,6,7,8- tetrahydroquinoline) turned out to be the most active derivative showing a potency similar to the reference compound dazoxiben (IC50 values 1.6 and 1.1 μM).